Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances
Earlier on Wednesday, Avalo Therapeutics, Inc. (NASDAQ:AVTX) appointed Rita Jain, M.D., to its Board of Directors. Dr Jain, who previously served as Executive Vice President and Chief Medical Officer at ChemoCentryx, joins the board at the company's crucial time and plans to advance the Phase 2 LOTUS trial in HS, with results expected in mid-2026.
A chemist in a laboratory analyzing data from the various therapeutic tests conducted.
H.C. Wainwright analysts have upgraded Avalo Therapeutics, Inc. (NASDAQ:AVTX) to Buy from Neutral, while setting the 12-month price target to $15.00, implying an upside of over 200%. The leading candidate, AVTX-009, is what the analysts believe will lead the future of the company. The firm highlights that the mechanism represents an optimal strategy, stating that the competitor data reinforces the effectiveness of this risk-mitigated approach in treating the condition.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2001, operates as a clinical-stage biotechnology company that develops treatments for immune dysregulation in the United States. The core offering of this Maryland-based company is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß.
While we acknowledge the potential of AVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Berkshire takes Kraft Heinz writedown, operating profit falls
(Reuters) -Warren Buffett's Berkshire Hathaway (BRK-A) (BRK-B) on Saturday wrote down part of its investment in Kraft Heinz (KHC), and reported a 4% decline in second-quarter operating profit as premiums from insurance underwriting fell. Berkshire also reported a 59% decline in net income, reflecting lower overall investment gains from its common stock holdings, as well as the Kraft Heinz writedown. Operating income totaled $11.16 billion, or about $7,760 per Class A share, compared with $11.6 billion a year earlier. Net income fell to $12.37 billion from $30.35 billion. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
3 minutes ago
- Yahoo
Willis Towers Watson Second Quarter 2025 Earnings: Beats Expectations
Willis Towers Watson (NASDAQ:WTW) Second Quarter 2025 Results Key Financial Results Revenue: US$2.26b (flat on 2Q 2024). Net income: US$331.0m (up 135% from 2Q 2024). Profit margin: 15% (up from 6.2% in 2Q 2024). EPS: US$3.34 (up from US$1.37 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Willis Towers Watson Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 38%. Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Insurance industry in the US. Performance of the American Insurance industry. The company's share price is broadly unchanged from a week ago. Risk Analysis Before you take the next step you should know about the 3 warning signs for Willis Towers Watson that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
3 minutes ago
- Yahoo
ASGN Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
ASGN (NYSE:ASGN) Second Quarter 2025 Results Key Financial Results Revenue: US$1.02b (down 1.4% from 2Q 2024). Net income: US$29.3m (down 38% from 2Q 2024). Profit margin: 2.9% (down from 4.6% in 2Q 2024). EPS: US$0.67 (down from US$1.03 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period ASGN Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 4.8%. Looking ahead, revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the IT industry in the US. Performance of the American IT industry. The company's shares are down 11% from a week ago. Risk Analysis You should learn about the 1 warning sign we've spotted with ASGN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio